180 related articles for article (PubMed ID: 10167067)
1. Regulating biotechnology: a rational-political model of policy development.
Wiktorowicz M; Deber R
Health Policy; 1997 May; 40(2):115-38. PubMed ID: 10167067
[TBL] [Abstract][Full Text] [Related]
2. Harmonization of HTA--based reimbursement and regulatory approval activities: a qualitative study.
Tsoi B; O'Reilly D; Masucci L; Drummond M; Goeree R
J Popul Ther Clin Pharmacol; 2015; 22(1):e78-89. PubMed ID: 25715384
[TBL] [Abstract][Full Text] [Related]
3. Harmonization of reimbursement and regulatory approval processes: a systematic review of international experiences.
Tsoi B; Masucci L; Campbell K; Drummond M; O'Reilly D; Goeree R
Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):497-511. PubMed ID: 23977976
[TBL] [Abstract][Full Text] [Related]
4. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
[TBL] [Abstract][Full Text] [Related]
5. What decision-makers want and what they have been getting.
McGregor M
Value Health; 2006; 9(3):181-5. PubMed ID: 16689712
[No Abstract] [Full Text] [Related]
6. Regulation of health-related technologies in Germany.
Perleth M; Busse R; Schwartz FW
Health Policy; 1999 Jan; 46(2):105-26. PubMed ID: 10346284
[TBL] [Abstract][Full Text] [Related]
7. The impact of the UK NHS purchaser-provider split on the 'rational' introduction of new medical technologies.
Rosen R; Mays N
Health Policy; 1998 Feb; 43(2):103-23. PubMed ID: 10177613
[TBL] [Abstract][Full Text] [Related]
8. Health technology adoption and the politics of governance in the UK.
Milewa T
Soc Sci Med; 2006 Dec; 63(12):3102-12. PubMed ID: 16982120
[TBL] [Abstract][Full Text] [Related]
9. Insurance coverage for experimental technologies.
Steinberg EP; Tunis S; Shapiro D
Health Aff (Millwood); 1995; 14(4):143-58. PubMed ID: 8690340
[TBL] [Abstract][Full Text] [Related]
10. Introduction: The challenge of developing oversight approaches to nanobiotechnology.
Paradise J; Wolf SM; Kuzma J; Ramachandran G; Kokkoli E
J Law Med Ethics; 2009; 37(4):543-5. PubMed ID: 20122099
[No Abstract] [Full Text] [Related]
11. Tougher rules aim to prevent gene flow into crops.
Hoag H
Nature; 2003 Mar; 422(6928):103. PubMed ID: 12634744
[No Abstract] [Full Text] [Related]
12. Health technology assessment and comparative effectiveness research: a pharmaceutical industry perspective.
Hao Y; Thomas A
Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):447-54. PubMed ID: 23977973
[TBL] [Abstract][Full Text] [Related]
13. The which-hunt: assembling health technologies for assessment and rationing.
Giacomini MK
J Health Polit Policy Law; 1999 Aug; 24(4):715-58. PubMed ID: 10503155
[TBL] [Abstract][Full Text] [Related]
14. INTRODUCTION OF HEALTH TECHNOLOGY ASSESSMENT FOR MEDICINES IN SLOVAKIA.
Tesar T; Hloska A; Wawruch M; Lehocka L; Snopkova M; Masarykova L
Int J Technol Assess Health Care; 2017 Jan; 33(3):345-349. PubMed ID: 28434416
[TBL] [Abstract][Full Text] [Related]
15. Australian guidelines for cost-effectiveness studies of pharmaceuticals: the thin end of the boomerang?
Drummond M
Pharmacoeconomics; 1992; 1(Suppl 1):61-9. PubMed ID: 10146934
[TBL] [Abstract][Full Text] [Related]
16. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
17. Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies.
Hailey D
Soc Sci Med; 1997 Aug; 45(4):563-81. PubMed ID: 9226782
[TBL] [Abstract][Full Text] [Related]
18. Current regulatory and legal considerations for follow-on biologics.
Kingham RF; Lietzan E
Clin Pharmacol Ther; 2008 Nov; 84(5):633-5. PubMed ID: 18716615
[No Abstract] [Full Text] [Related]
19. Regulatory considerations in the development of protein pharmaceuticals.
Beatrice MG
Pharm Biotechnol; 2002; 14():405-56. PubMed ID: 12189729
[No Abstract] [Full Text] [Related]
20. Health-related biotechnology in Africa: managing the legislative and regulatory issues.
Andanda AP
Afr J Med Med Sci; 2007; 36 Suppl():55-61. PubMed ID: 17703566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
